Ulat ng mga kita sa Novavax (NVAX) Q2 2023
Pagbabahagi ng jumped on Tuesday after the Covid vaccine maker reported a surprise second-quarter profit. Novavax posted net income of $58 million, or 58 cents per share, for the quarter. That compares with a net loss of $510.5 million, or $6.53 per share, for the same quarter last year. The biotech company generated second-quarter sales of $424.4 million, up from the $185.9 million from the same period a year ago. Here‘s what Novavax reported compared with Wall Street’s expectations, based on a survey of analysts by Refinitiv. Mga kita bawat bahagi: 58 cents per share, vs. a loss of $1.39 per share expected Kita: $424.43 million, vs. $239.2 million expected Novavax CEO John Jacobs told CNBC that the company pulled forward some revenue that “might have drifted” into the third quarter from prior Covid vaccine purchase agreements, recognizing those sales instead in the second quarter. He noted there will be “little to no sales” in the third quarter because the Food and Drug Administration won‘t make a decision on Novavax’s new Covid shot until late September. The company can only start rolling out the vaccine to the public after a potential approval from the agency. Most of Novavaxs revenue in the third quarter will come from grants, according
